Kyinno Biotechnology, Inc.
Stephanie (Lu) Wang serves as the Head of Business Development at KYINNO BIOTECHNOLOGY Inc. since January 2022, where responsibilities include advancing oncology drug discovery and customized product development through a wide range of preclinical services. Previously, Stephanie held the position of Director of Business Development at TargetMol from August 2018 to March 2023 and was an Account Manager at Selleck Chemicals LLC between November 2016 and July 2018. Stephanie obtained dual Master's degrees in Molecular Biology and Biology/Biological Sciences from Fudan University, completed between 2008 and 2011.
This person is not in any teams
This person is not in any offices
Kyinno Biotechnology, Inc.
Kyinno Biotechnology: Pioneering Oncology Research as a Premier CRO Global Presence: Strategically positioned in Beijing and Boston, Kyinno Biotechnology leads in global oncology research and development. Advanced Resources: With over 8,000 engineered cell lines, we specialize in customized research services for drug R&D, both in vitro and in vivo. Innovative Platforms: Our MPSA-AB5000 platform exemplifies our prowess in high-throughput CART and antibody drug off-target screening, showcasing our technological capabilities. Extensive Facilities: Our state-of-the-art laboratories span over 6,000 square meters, equipped to drive forward pioneering research in oncology. Global Collaboration: Partnering with over 700 entities worldwide, we excel in building enduring relationships in the scientific community. Our Ethos: Service, Focus, Quality, and Efficiency define our approach, positioning us as a reliable partner in the quest to conquer cancer. Connect with Us: Stay informed on the latest developments at Kyinno Biotechnology by following us. We are actively interested in establishing long-term partnerships to explore new frontiers in our field.